. 2019 Jun 17;19:129. doi: 10.1186/s12886-019-1129-7

Table 4.

Results of analyses by injected agent

4–1. ERG responses before and after injection of ranibzumab.
ranibizumab n = 50 (male, 22; female, 28)
mean age		68.1 ± 13.5 y.o.
injected eye	Phase 1	Phase 2	Phase 3	repeated measure test
implicit time	31.6 ± 3.45	32.0 ± 3.45^a	32.5 ± 3.57^a	p < 0.000001
(msec.)		p = 0.012	p < 0.000001	p < 0.000001
amplitude	7.18 ± 5.34	6.68 ± 5.60	8.21 ± 9.97	p = 0.377
(uV)		p = 1	p = 1	p = 0.377
non-injected eye	Phase 1	Phase 2	Phase 3	repeated measure test
implicit time	30.8 ± 3.24	31.3 ± 3.51	31.5 ± 3.62^a	p = 0.0029
(msec.)		p = 0.062	p = 0.0052	p = 0.0029
amplitude	8.21 ± 6.00	7.32 ± 4.79	8.31 ± 5.54	p = 0.144
(uV)		p = 0.45	p = 1	p = 0.144
4–2. ERG responses before and after injection of aflibercept.
aflibercept n = 28 (male: 21, female: 7)
mean age		70.1 ± 11.0 y.o.
injected eye	Phase 1	Phase 2	Phase 3	repeated measure test
implicit time	30.9 ± 2.43	31.4 ± 2.09^a	31.8 ± 2.55^a	p = 0.0032
(msec.)		p = 0.020	p = 0.000002	p = 0.0032
amplitude	11.5 ± 5.41	10.0 ± 6.49	11.8 ± 6.45	p = 0.088
(uV)		p = 0.4	p = 1	p = 0.088
non-injected eye	Phase 1	Phase 2	Phase 3	repeated measure test
implicit time	30.2 ± 3.33	31.0 ± 2.36	31.3 ± 2.85^a	p = 0.0040
(msec.)		p = 0.17	p = 0.0039	p = 0.0040
amplitude	11.7 ± 6.86	12.5 ± 8.23	11.8 ± 6.80	p = 0.511
(uV)		p = 1	p = 1	p = 0.511

The results of 28 Hz flicker electroretinogram components classified by injected agent. The ERGs were recorded before the injection (Phase 1), within 2 h after the injection (Phase 2), and 2 to 24 h after the injection (Phase 3)

mean ± standard deviation

^a; significant difference by the repeated measure test and by the post hoc test compared with Phase 1